NKGen Biotech, Inc. Common Stock
NKGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | -0.29 | 0.00 |
| FCF Yield | -110.54% | -51.85% | -18.55% | -16.33% |
| EV / EBITDA | -0.70 | -2.18 | -5.79 | -8.41 |
| Quality | ||||
| ROIC | -112,492.96% | 229.19% | -178.76% | -156.88% |
| Gross Margin | 0.00% | 0.00% | 76.62% | 92.96% |
| Cash Conversion Ratio | 0.47 | 0.26 | 0.84 | 0.84 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | 425,332.09% | 752,336.52% |
| Free Cash Flow Growth | 5.07% | 3.19% | -13.56% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -0.70 | -0.51 | -2.49 |
| Interest Coverage | -9.90 | -39.93 | -10.56 | -16.62 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,349.63 | -19,315.77 | -20,796.26 |